To learn more, please call our Research Department at (513) 751-2273 or email
mhoelle@ohcare.com
| first line |
| Study number: |
MM 23 SCRI |
| Protocol title: |
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients with Multiple Myeloma Who are Not Candidates for High-Dose Chemotherapy |
| Status |
Open
|